Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer |
| |
| Authors: | Bo Yang Guo-qiang Liao Xiao-fei Wen Wei-hua Chen Sheng Cheng Jens-Uwe Stolzenburg Roman Ganzer Jochen Neuhaus |
| |
| Institution: | 1.Department of Urology, Zhoupu Hospital,Shanghai University of Medicine & Health Sciences,Shanghai,China;2.Department of Urology, Shanghai East Hospital,Tongji University School of Medicine,Shanghai,China;3.Department of Urology, Sir Run Run Shaw Hospital, School of Medicine,Zhejiang University,Hangzhou,China;4.Department of Urology,University Hospital of Leipzig,Leipzig,Germany;5.Division of Urology, Research Laboratory,University of Leipzig,Leipzig,Germany |
| |
| Abstract: | Prostate cancer (PCa) is the second most common male cancer worldwide and the fifth leading cause of death from cancer in men. Early detection and risk stratification is the most effective way to improve the survival of PCa patients. Current PCa biomarkers lack sufficient sensitivity and specificity to cancer. Metabolite biomarkers are evolving as a new diagnostic tool. This review is aimed to evaluate the potential of metabolite biomarkers for early detection, risk assessment, and monitoring of PCa. Of the 154 identified publications, 27 and 38 were original papers on urine and serum metabolomics, respectively. Nuclear magnetic resonance (NMR) is a promising method for measuring concentrations of metabolites in complex samples with good reproducibility, high sensitivity, and simple sample processing. Especially urine-based NMR metabolomics has the potential to be a cost-efficient method for the early detection of PCa, risk stratification, and monitoring treatment efficacy. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
